Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Neutrophils dominate the immune cell composition in non-small cell lung cancer.

Kargl J, Busch SE, Yang GH, Kim KH, Hanke ML, Metz HE, Hubbard JJ, Lee SM, Madtes DK, McIntosh MW, Houghton AM.

Nat Commun. 2017 Feb 1;8:14381. doi: 10.1038/ncomms14381.

2.

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.

Laszlo GS, Harrington KH, Gudgeon CJ, Beddoe ME, Fitzgibbon MP, Ries RE, Lamba JK, McIntosh MW, Meshinchi S, Walter RB.

Oncotarget. 2016 Jul 12;7(28):43281-43294. doi: 10.18632/oncotarget.9674.

3.

Ovarian Cancer Early Detection Needs Better Imaging, Not Better Algorithms or Biomarkers.

McIntosh MW, Drescher C, Fitzgibbon MM.

J Clin Oncol. 2016 Jan 10;34(2):199-200. doi: 10.1200/JCO.2015.63.7843. Epub 2015 Nov 16. No abstract available.

PMID:
26573076
4.

Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma.

Chen R, Dawson DW, Pan S, Ottenhof NA, de Wilde RF, Wolfgang CL, May DH, Crispin DA, Lai LA, Lay AR, Waghray M, Wang S, McIntosh MW, Simeone DM, Maitra A, Brentnall TA.

Lab Invest. 2015 Jan;95(1):43-55. doi: 10.1038/labinvest.2014.128. Epub 2014 Oct 27.

5.

Quantitative glycoproteomics analysis reveals changes in N-glycosylation level associated with pancreatic ductal adenocarcinoma.

Pan S, Chen R, Tamura Y, Crispin DA, Lai LA, May DH, McIntosh MW, Goodlett DR, Brentnall TA.

J Proteome Res. 2014 Mar 7;13(3):1293-306. doi: 10.1021/pr4010184. Epub 2014 Jan 28.

6.

Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient mice.

Chou J, Fitzgibbon MP, Mortales CL, Towlerton AM, Upton MP, Yeung RS, McIntosh MW, Warren EH.

PLoS One. 2013 Nov 20;8(11):e79874. doi: 10.1371/journal.pone.0079874. eCollection 2013.

7.

Metabolomic profiling of urine: response to a randomised, controlled feeding study of select fruits and vegetables, and application to an observational study.

May DH, Navarro SL, Ruczinski I, Hogan J, Ogata Y, Schwarz Y, Levy L, Holzman T, McIntosh MW, Lampe JW.

Br J Nutr. 2013 Nov;110(10):1760-70. doi: 10.1017/S000711451300127X. Epub 2013 May 9.

8.

Statistical inference from multiple iTRAQ experiments without using common reference standards.

Herbrich SM, Cole RN, West KP Jr, Schulze K, Yager JD, Groopman JD, Christian P, Wu L, O'Meally RN, May DH, McIntosh MW, Ruczinski I.

J Proteome Res. 2013 Feb 1;12(2):594-604. doi: 10.1021/pr300624g. Epub 2013 Jan 16.

9.

Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.

Drescher CW, Shah C, Thorpe J, O'Briant K, Anderson GL, Berg CD, Urban N, McIntosh MW.

J Clin Oncol. 2013 Jan 20;31(3):387-92. doi: 10.1200/JCO.2012.43.6691. Epub 2012 Dec 17.

10.

Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.

Urban N, Thorpe J, Karlan BY, McIntosh MW, Palomares MR, Daly MB, Paley P, Drescher CW.

Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2087-94. doi: 10.1158/1055-9965.EPI-12-0616. Epub 2012 Sep 7.

11.

Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.

Li CI, Mirus JE, Zhang Y, Ramirez AB, Ladd JJ, Prentice RL, McIntosh MW, Hanash SM, Lampe PD.

Breast Cancer Res Treat. 2012 Sep;135(2):611-8. doi: 10.1007/s10549-012-2204-4. Epub 2012 Aug 19.

12.

Large-scale quantitative glycoproteomics analysis of site-specific glycosylation occupancy.

Pan S, Tamura Y, Chen R, May D, McIntosh MW, Brentnall TA.

Mol Biosyst. 2012 Nov;8(11):2850-6. doi: 10.1039/c2mb25268f. Epub 2012 Aug 14.

13.

Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition.

Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB, Mallick P.

Mol Cancer Ther. 2012 May;11(5):1071-81. doi: 10.1158/1535-7163.MCT-11-0852. Epub 2012 Mar 12.

14.

Proteomics portrait of archival lesions of chronic pancreatitis.

Pan S, Chen R, Stevens T, Bronner MP, May D, Tamura Y, McIntosh MW, Brentnall TA.

PLoS One. 2011;6(11):e27574. doi: 10.1371/journal.pone.0027574. Epub 2011 Nov 23.

15.

Potential role of HE4 in multimodal screening for epithelial ovarian cancer.

Urban N, Thorpe JD, Bergan LA, Forrest RM, Kampani AV, Scholler N, O'Briant KC, Anderson GL, Cramer DW, Berg CD, McIntosh MW, Hartge P, Drescher CW.

J Natl Cancer Inst. 2011 Nov 2;103(21):1630-4. doi: 10.1093/jnci/djr359. Epub 2011 Sep 14.

16.

Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma.

Fang Q, Kani K, Faca VM, Zhang W, Zhang Q, Jain A, Hanash S, Agus DB, McIntosh MW, Mallick P.

PLoS One. 2011;6(7):e23090. doi: 10.1371/journal.pone.0023090. Epub 2011 Jul 29.

17.

A targeted proteomics-based pipeline for verification of biomarkers in plasma.

Whiteaker JR, Lin C, Kennedy J, Hou L, Trute M, Sokal I, Yan P, Schoenherr RM, Zhao L, Voytovich UJ, Kelly-Spratt KS, Krasnoselsky A, Gafken PR, Hogan JM, Jones LA, Wang P, Amon L, Chodosh LA, Nelson PS, McIntosh MW, Kemp CJ, Paulovich AG.

Nat Biotechnol. 2011 Jun 19;29(7):625-34. doi: 10.1038/nbt.1900.

18.

Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer.

Schoenherr RM, Kelly-Spratt KS, Lin C, Whiteaker JR, Liu T, Holzman T, Coleman I, Feng LC, Lorentzen TD, Krasnoselsky AL, Wang P, Liu Y, Gurley KE, Amon LM, Schepmoes AA, Moore RJ, Camp DG 2nd, Chodosh LA, Smith RD, Nelson PS, McIntosh MW, Kemp CJ, Paulovich AG.

Proteomics Clin Appl. 2011 Apr;5(3-4):179-88. doi: 10.1002/prca.201000037. Epub 2011 Feb 15.

19.

Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling.

Pan S, Chen R, Crispin DA, May D, Stevens T, McIntosh MW, Bronner MP, Ziogas A, Anton-Culver H, Brentnall TA.

J Proteome Res. 2011 May 6;10(5):2359-76. doi: 10.1021/pr101148r. Epub 2011 Mar 28.

20.

A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.

Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD; PLCO Project Team.

Cancer Prev Res (Phila). 2011 Mar;4(3):375-83. doi: 10.1158/1940-6207.CAPR-10-0193.

21.

Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N.

Cancer Prev Res (Phila). 2011 Mar;4(3):365-74. doi: 10.1158/1940-6207.CAPR-10-0195.

22.

Detection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users.

Pitteri SJ, Amon LM, Busald Buson T, Zhang Y, Johnson MM, Chin A, Kennedy J, Wong CH, Zhang Q, Wang H, Lampe PD, Prentice RL, McIntosh MW, Hanash SM, Li CI.

Cancer Res. 2010 Nov 1;70(21):8598-606. doi: 10.1158/0008-5472.CAN-10-1676. Epub 2010 Oct 19.

23.

Pilot study of blood biomarker candidates for detection of pancreatic cancer.

Chen R, Crispin DA, Pan S, Hawley S, McIntosh MW, May D, Anton-Culver H, Ziogas A, Bronner MP, Brentnall TA.

Pancreas. 2010 Oct;39(7):981-8. doi: 10.1097/MPA.0b013e3181dac920.

24.

Use of a single-chain antibody library for ovarian cancer biomarker discovery.

Ramirez AB, Loch CM, Zhang Y, Liu Y, Wang X, Wayner EA, Sargent JE, Sibani S, Hainsworth E, Mendoza EA, Eugene R, Labaer J, Urban ND, McIntosh MW, Lampe PD.

Mol Cell Proteomics. 2010 Jul;9(7):1449-60. doi: 10.1074/mcp.M900496-MCP200. Epub 2010 May 13.

25.

Proteomics on Fixed Tissue Specimens - A Review.

Reimel BA, Pan S, May DH, Shaffer SA, Goodlett DR, McIntosh MW, Yerian LM, Bronner MP, Chen R, Brentnall TA.

Curr Proteomics. 2009 Apr 1;6(1):63-69.

26.

Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.

Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD, Urban N, Drescher CW.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1365-72. doi: 10.1158/1055-9965.EPI-08-1034.

27.

Quantitative proteomics investigation of pancreatic intraepithelial neoplasia.

Pan S, Chen R, Reimel BA, Crispin DA, Mirzaei H, Cooke K, Coleman JF, Lane Z, Bronner MP, Goodlett DR, McIntosh MW, Traverso W, Aebersold R, Brentnall TA.

Electrophoresis. 2009 Apr;30(7):1132-44. doi: 10.1002/elps.200800752.

28.

Mass spectrometry based targeted protein quantification: methods and applications.

Pan S, Aebersold R, Chen R, Rush J, Goodlett DR, McIntosh MW, Zhang J, Brentnall TA.

J Proteome Res. 2009 Feb;8(2):787-97. doi: 10.1021/pr800538n. Review.

29.

Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease.

Fang Q, Strand A, Law W, Faca VM, Fitzgibbon MP, Hamel N, Houle B, Liu X, May DH, Poschmann G, Roy L, Stühler K, Ying W, Zhang J, Zheng Z, Bergeron JJ, Hanash S, He F, Leavitt BR, Meyer HE, Qian X, McIntosh MW.

Mol Cell Proteomics. 2009 Mar;8(3):451-66. doi: 10.1074/mcp.M800231-MCP200. Epub 2008 Nov 4.

30.

Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery.

Scholler N, Gross JA, Garvik B, Wells L, Liu Y, Loch CM, Ramirez AB, McIntosh MW, Lampe PD, Urban N.

J Transl Med. 2008 Jul 24;6:41. doi: 10.1186/1479-5876-6-41.

31.

Systematic evaluation of candidate blood markers for detecting ovarian cancer.

Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW, Brown PO, Nelson BH, Urban N.

PLoS One. 2008 Jul 9;3(7):e2633. doi: 10.1371/journal.pone.0002633.

32.

Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.

Faça VM, Ventura AP, Fitzgibbon MP, Pereira-Faça SR, Pitteri SJ, Green AE, Ireton RC, Zhang Q, Wang H, O'Briant KC, Drescher CW, Schummer M, McIntosh MW, Knudsen BS, Hanash SM.

PLoS One. 2008 Jun 18;3(6):e2425. doi: 10.1371/journal.pone.0002425.

33.

A mouse to human search for plasma proteome changes associated with pancreatic tumor development.

Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, Hanash SM.

PLoS Med. 2008 Jun 10;5(6):e123. doi: 10.1371/journal.pmed.0050123.

34.

Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells.

Pitteri SJ, Faca VM, Kelly-Spratt KS, Kasarda AE, Wang H, Zhang Q, Newcomb L, Krasnoselsky A, Paczesny S, Choi G, Fitzgibbon M, McIntosh MW, Kemp CJ, Hanash SM.

J Proteome Res. 2008 Apr;7(4):1481-9. doi: 10.1021/pr7007994. Epub 2008 Feb 27.

PMID:
18311905
35.

Use of high density antibody arrays to validate and discover cancer serum biomarkers.

Loch CM, Ramirez AB, Liu Y, Sather CL, Delrow JJ, Scholler N, Garvik BM, Urban ND, McIntosh MW, Lampe PD.

Mol Oncol. 2007 Dec;1(3):313-20. doi: 10.1016/j.molonc.2007.08.004. Epub 2007 Aug 30.

36.

Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer.

Whiteaker JR, Zhang H, Zhao L, Wang P, Kelly-Spratt KS, Ivey RG, Piening BD, Feng LC, Kasarda E, Gurley KE, Eng JK, Chodosh LA, Kemp CJ, McIntosh MW, Paulovich AG.

J Proteome Res. 2007 Oct;6(10):3962-75. Epub 2007 Aug 21.

PMID:
17711321
37.

Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.

McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4422-8.

38.

Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.

Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, Kim NW, McIntosh MW.

Gynecol Oncol. 2007 Jul;106(1):112-8. Epub 2007 May 8.

PMID:
17490732
39.

Head-to-head comparison of serum fractionation techniques.

Whiteaker JR, Zhang H, Eng JK, Fang R, Piening BD, Feng LC, Lorentzen TD, Schoenherr RM, Keane JF, Holzman T, Fitzgibbon M, Lin C, Zhang H, Cooke K, Liu T, Camp DG 2nd, Anderson L, Watts J, Smith RD, McIntosh MW, Paulovich AG.

J Proteome Res. 2007 Feb;6(2):828-36.

PMID:
17269739
40.

Comparing adaptive and non-adaptive algorithms for cancer early detection with novel biomarkers.

Sato AH, Anderson GL, Urban N, McIntosh MW.

Cancer Biomark. 2006;2(3-4):151-62.

PMID:
17192068
41.

Modification of host lipid raft proteome upon hepatitis C virus replication.

Mannová P, Fang R, Wang H, Deng B, McIntosh MW, Hanash SM, Beretta L.

Mol Cell Proteomics. 2006 Dec;5(12):2319-25. Epub 2006 Aug 29.

42.

Quality control metrics for LC-MS feature detection tools demonstrated on Saccharomyces cerevisiae proteomic profiles.

Piening BD, Wang P, Bangur CS, Whiteaker J, Zhang H, Feng LC, Keane JF, Eng JK, Tang H, Prakash A, McIntosh MW, Paulovich A.

J Proteome Res. 2006 Jul;5(7):1527-34.

PMID:
16823959
43.
44.

Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments.

Rauch A, Bellew M, Eng J, Fitzgibbon M, Holzman T, Hussey P, Igra M, Maclean B, Lin CW, Detter A, Fang R, Faca V, Gafken P, Zhang H, Whiteaker J, States D, Hanash S, Paulovich A, McIntosh MW.

J Proteome Res. 2006 Jan;5(1):112-21. Erratum in: J Proteome Res. 2006 Apr;5(4):1024. Whitaker, Jeffrey [corrected to Whiteaker, Jeffrey].

PMID:
16396501
45.

Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.

Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML.

J Clin Oncol. 2006 Feb 10;24(5):762-8. Epub 2006 Jan 3.

PMID:
16391298
46.

Detection of hypermethylated genes in women with and without cervical neoplasia.

Feng Q, Balasubramanian A, Hawes SE, Toure P, Sow PS, Dem A, Dembele B, Critchlow CW, Xi L, Lu H, McIntosh MW, Young AM, Kiviat NB.

J Natl Cancer Inst. 2005 Feb 16;97(4):273-82.

PMID:
15713962
47.

Characteristics and presenting complaints of outpatients with undiagnosed HIV infection: potential utility in selecting subjects for HIV testing.

Sow PS, Hawes SE, Critchlow CW, McIntosh MW, Diop A, Diouf MB, Gottlieb GS, Starling AK, Coll-Seck AM, Kiviat NB.

J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1520-8.

PMID:
15602131
48.

Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I.

Gynecol Oncol. 2004 Oct;95(1):9-15.

49.

Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening.

Drescher CW, Nelson J, Peacock S, Andersen MR, McIntosh MW, Urban N.

Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):600-6.

50.

Ovarian cancer screening.

Urban N, McIntosh MW, Andersen M, Karlan BY.

Hematol Oncol Clin North Am. 2003 Aug;17(4):989-1005, ix. Review.

PMID:
12959188

Supplemental Content

Loading ...
Support Center